Jazz Pharmaceuticals Plc Revenue Growth Rates (JAZZ), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Jazz Pharmaceuticals Plc  (NASDAQ: JAZZ)
 

JAZZ's Revenue Growth by Quarter and Year

Jazz Pharmaceuticals Plc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/JAZZ/growth
https://api.csimarket.com/api/v1/companies/JAZZ/fundamentals
https://api.csimarket.com/api/v1/companies/JAZZ/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
JAZZ Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 1,243.00
2nd Quarter June 1,208.30
1st Quarter March 1,068.90
FY 3,520.20

JAZZs Annual Revenue
Jazz Pharmaceuticals Plc's Revenue in the fiscal year 2025 $ 4,267.59 millions
Jazz Pharmaceuticals Plc's Revenue in the fiscal year 2024 $ 4,068.95 millions
Jazz Pharmaceuticals Plc's Revenue in the fiscal year 2023 $ 3,834.20 millions
Jazz Pharmaceuticals Plc's Revenue in the fiscal year 2022 $ 3,659.37 millions
Jazz Pharmaceuticals Plc's Revenue in the fiscal year 2021 $ 3,094.24 millions




JAZZ Revenue third quarter 2026 Y/Y Growth Comment
Jazz Pharmaceuticals Plc reported Revenue increase of 10.38% year on year in the third quarter 2026, to $ 1,243.00 millions, this is lower than Jazz Pharmaceuticals Plc's recent average Revenue improvement of 22.65%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 120 other companies have achieved higher Revenue growth. While Jazz Pharmaceuticals Plc' s Revenue growth of 10.38% ranks overall at the positon no. 2590 in the third quarter 2026.


JAZZ Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 10.38 %
2nd Quarter June 15.55 %
1st Quarter March 19.05 %
FY   -

Financial Statements
Jazz Pharmaceuticals Plc's third quarter 2026 Revenue $ 1,243.00 millions JAZZ's Income Statement
Jazz Pharmaceuticals Plc's third quarter 2025 Revenue $ 1,126.11 millions Quarterly JAZZ's Income Statement


JAZZ Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 2.87 %
2nd Quarter June 13.04 %
1st Quarter March -10.77 %
FY (Year on Year)   -


Back to JAZZ Growth rate Comparisons >> Back to JAZZ Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #121
Healthcare Sector #373
Overall #2590

Revenue Y/Y Growth Statistics
High Average Low
119.32 % 22.65 % 0 %
(Dec 31 2012)   (Dec 31 2011)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #121
Healthcare Sector #373
Overall #2590
Revenue Y/Y Growth Statistics
High Average Low
119.32 % 22.65 % 0 %
(Dec 31 2012)   (Dec 31 2011)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Jazz Pharmaceuticals Plc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
35.49 % 5.66 % -39.09 %
(Sep 30 2012)  


JAZZ's III. Quarter Q/Q Revenue Comment
Jazz Pharmaceuticals Plc achieved in the III. Quarter 2026 below company average Revenue growth of 2.87% quarter on quarter, to $ 1,243.00 millions.

Within Major Pharmaceutical Preparations industry 52 other companies have achieved higher Revenue quarter on quarter growth. While Jazz Pharmaceuticals Plc's Revenue growth quarter on quarter, overall rank is 707.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #53
Healthcare Sector #119
Overall #707
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #53
Healthcare Sector #119
Overall #707
Revenue Q/Q Growth Statistics
High Average Low
35.49 % 5.66 % -39.09 %
(Sep 30 2012)  


JAZZ's III. Quarter Q/Q Revenue Comment
Jazz Pharmaceuticals Plc achieved in the III. Quarter 2026 below company average Revenue growth of 2.87% quarter on quarter, to $ 1,243.00 millions.

Within Major Pharmaceutical Preparations industry 52 other companies have achieved higher Revenue quarter on quarter growth. While Jazz Pharmaceuticals Plc's Revenue growth quarter on quarter, overall rank is 707.


Jazz Pharmaceuticals Plc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 4,718.13
Y / Y Revenue Growth (TTM) 13.48 %
Year on Year Revenue Growth Overall Ranking # 2136
Seqeuential Revenue Change (TTM) 2.54 %
Seq. Revenue Growth (TTM) Overall Ranking # 2590


Cumulative Revenue growth Comment
Although Jazz Pharmaceuticals Plc's Annual Revenue growth year on year were below company's average 22.65% , Revenue announced in the Sep 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 13.48% year on year, from 12.59% in Jun 30 2026.

In the Healthcare sector 316 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 676 to 2136.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 121
Healthcare Sector # 317
Overall # 2136

Revenue TTM Y/Y Growth Statistics
High Average Low
119.32 %
 22.65 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 121
Sector # 373
S&P 500 # 2590
Cumulative Revenue growth Comment
Although Jazz Pharmaceuticals Plc's Annual Revenue growth year on year were below company's average 22.65% , Revenue announced in the Sep 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 13.48% year on year, from 12.59% in Jun 30 2026.

In the Healthcare sector 316 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 676 to 2136.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 121
Healthcare Sector # 317
Overall # 2136

Revenue TTM Y/Y Growth Statistics
High Average Low
119.32 %
22.65 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 121
Sector # 373
S&P 500 # 2590




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
JAZZ's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Supernus Pharmaceuticals inc 18.05%$ 18.047 millions
Harvard Apparatus Regenerative Technology Inc 17.89%$ 17.886 millions
Outset Medical Inc 17.51%$ 17.510 millions
Alnylam Pharmaceuticals Inc 16.74%$ 16.738 millions
IMPACT BIOMEDICAL INC.16.67%$ 16.667 millions
Rigel Pharmaceuticals Inc16.45%$ 16.452 millions
Si bone inc 16.42%$ 16.424 millions
Ars Pharmaceuticals Inc 16.03%$ 16.027 millions
Atricure Inc 15.84%$ 15.839 millions
American Shared Hospital Services15.76%$ 15.761 millions
Ardelyx inc 15.70%$ 15.704 millions
Novocure Limited15.67%$ 15.666 millions
Penumbra Inc15.64%$ 15.636 millions
Orasure Technologies Inc15.45%$ 15.445 millions
Electromed Inc 15.34%$ 15.342 millions
Irhythm Holdings Inc 15.34%$ 15.339 millions
P3 Health Partners Inc 14.80%$ 14.798 millions
Msa Safety Inc14.72%$ 14.716 millions
Ensign Group Inc14.47%$ 14.471 millions
Abbott Laboratories14.46%$ 14.460 millions
Electrocore Inc 14.40%$ 14.404 millions
Allogene Therapeutics Inc 14.29%$ 14.286 millions
Tandem Diabetes Care Inc 14.26%$ 14.257 millions
Iradimed Corporation14.15%$ 14.154 millions
Apyx Medical Corp14.09%$ 14.093 millions
Incyte Corporation14.00%$ 13.999 millions
Aurinia Pharmaceuticals Inc 13.93%$ 13.926 millions
Indivior Pharmaceuticals Inc 13.74%$ 13.738 millions
Cryoport inc 13.54%$ 13.535 millions
Neuronetics Inc 13.35%$ 13.350 millions


About Jazz Pharmaceuticals Plc Revenue Growth Rates (JAZZ), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Jazz Pharmaceuticals Plc (CIK 1232524).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001232524-26-000057
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Jazz Pharmaceuticals Plc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.